Records whose title is actually about this topic. Use a country filter if the list is still too broad.
Records
Bill· SS. 1130 (118th)referred
United States · United States Congress · 30 March 2023
Health Care Prices Revealed and Information to Consumers Explained Transparency Act or the Health Care PRICE Transparency Act This bill provides statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. Specifically, hospitals must publish in their list of standard charges certain rates negotiated with insurers, discounts for cash payments, and billing codes. Further, hospitals generally must publish the standard charges for the services provided by the hospital that may be scheduled in advance. Additionally, insurance plans must publish the in-network and out-of-network charges for covered items and services and the negotiated prices for covered prescription drugs. Plans must provide a tool for consumers to search for this cost information. Consumers also may request additional information about the costs of specific items or services under their plans.
Bill· SS. 1158 (118th)referred
United States · United States Congress · 30 March 2023
Health Savings Act of 2023 This bill modifies the requirements for health savings accounts (HSAs) to rename high deductible health plans as HSA-qualified health plans; allow spouses who have both attained age 55 to make catch-up contributions to the same HSA; make Medicare Part A (hospital insurance benefits) beneficiaries eligible to participate in an HSA; allow individuals eligible for hospital care or medical services under a program of the Indian Health Service or a tribal organization to participate in an HSA; allow members of a health care sharing ministry to participate in an HSA; allow individuals who receive primary care services in exchange for a fixed periodic fee or payment, or who receive health care benefits from an on-site medical clinic of an employer, to participate in an HSA; include amounts paid for prescription and over-the-counter medicines or drugs as qualified medical expenses for which distributions from an HSA or other tax-preferred savings accounts may be used; increase the limits on HSA contributions to match the sum of the annual deductible and out-of-pocket expenses permitted under a high deductible health plan; and allow HSA distributions to be used to purchase health insurance coverage. The bill also (1) exempts HSAs from creditor claims in bankruptcy, and (2) reauthorizes Medicaid health opportunity accounts. The bill allows a medical care tax deduction for (1) exercise equipment, physical fitness programs, and membership at a fitness facility; (2) nutritional and dietary supplements; and (3) periodic fees paid to a primary care physician and amounts paid for pre-paid primary care services.
Bill· SS. 1140 (118th)referred
United States · United States Congress · 30 March 2023
Ensuring Access to General Surgery Act of 2023 This bill requires the Health Resources and Services Administration (HRSA) to study access by underserved populations to general surgeons. Specifically, HRSA must study (1) whether the health professional shortage area designation under the National Health Service Corps (NHSC) program accurately assesses adequacy of access to general surgeons, (2) whether another measure would be more accurate, and (3) potential methodologies for designating general surgery shortage areas. (The NHSC provides scholarships and student loan repayment awards to primary care, dental care, and mental health care providers who agree to work in areas that HRSA designates as having a shortage of those particular types of providers.) HRSA must also publish data comparing the availability and need of general surgery services in urban, suburban, and rural areas. On the basis of its study, HRSA may establish a methodology for designating general surgery shortage areas and make such designations. If any designations are made, HRSA must publish a list of general surgery shortage areas.
Bill· SS. 1134 (118th)referred
United States · United States Congress · 30 March 2023
Creating Efficiency in Foreign Facility Inspections Act This bill prohibits, with some exceptions, the Food and Drug Administration (FDA) from providing notification in advance of a planned inspection of an establishment located outside of the United States that is engaged in drug manufacturing, processing, packing, or holding. Specifically, the FDA may not provide such an establishment advance notification of a planned inspection unless (1) advance notification is required by the laws of the country where the establishment is located; (2) providing advance notification is needed to protect the public health; or (3) the inspection in question is a preapproval, prelicensure, or for-cause inspection. If the FDA must provide advance notification, it must minimize the time between the notification and the inspection. If an establishment is located in a country that, on or after the date this bill is enacted, enacts a law requiring advance notification of inspections, the drug manufacturer must agree to waive the right to enforce the requirement, to the extent expressly permitted by the law.
Bill· SS. 1077 (118th)referred
United States · United States Congress · 30 March 2023
Home-Based Telemental Health Care Act of 2023 This bill establishes a grant program to fund demonstration projects to provide in-home mental health and substance use services to medically underserved individuals in rural areas or in the farming, fishing, and forestry industries. Specifically, the Department of Health and Human Services (HHS) must award grants to public or nonprofit telemental health provider networks to deliver, and evaluate the impact of, home-based telemental health and substance use services for such individuals. HHS must consult with the Rural Health Liaison of the Department of Agriculture on the grants.
Bill· SS. 1150 (118th)referred
United States · United States Congress · 30 March 2023
National Nursing Workforce Center Act of 2023 This bill sets out a pilot program to support state agencies, state boards of nursing, nursing schools, or other eligible entities with establishing or expanding state-based nursing workforce centers that carry out research, planning, and programs to address nursing shortages, nursing education, and other matters affecting the nursing workforce. The bill also expands the authority of the Health Resources and Services Administration (HRSA) to establish health workforce research centers and specifically requires that HRSA establish a center focused on nursing.
Bill· SS. 1139 (118th)referred
United States · United States Congress · 30 March 2023
Lower Drug Costs for Families Act This bill applies certain Medicare prescription drug rebate requirements to prescription drugs that are available under private health insurance. Current law requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for brand-name drugs without generic equivalents under Medicare that (1) cost $100 or more per year per individual, and (2) for which prices increase faster than inflation. Manufacturers that fail to comply are subject to civil penalties. The bill applies these requirements to prescription drugs that are available in the commercial market under private health insurance. It also indexes rebate calculations to drug prices in 2016 (as opposed to 2021).
Bill· SS. 1131 (118th)referred
United States · United States Congress · 30 March 2023
Drug Price Transparency Act of 202 3 This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws. Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.
Bill· SS. 1110 (118th)referred
United States · United States Congress · 30 March 2023
Rural Hospital Support Act This bill modifies and extends certain payment adjustments for rural hospitals under Medicare's inpatient prospective payment system. Specifically, the bill indexes payment adjustments for sole community hospitals and Medicare-dependent hospitals to FY2016 operating costs, if it results in higher payments for such hospitals. The bill also makes payment adjustments for Medicare-dependent hospitals and low-volume hospitals permanent (the adjustments currently expire at the end of FY2024).
Bill· SS. 1113 (118th)referred
United States · United States Congress · 30 March 2023
Nurse Staffing Standards for Patient Safety and Quality Care Act of 2023 This bill requires hospitals to implement and submit to the Department of Health and Human Services (HHS) a staffing plan that complies with specified minimum nurse-to-patient ratios by unit. Hospitals must post a notice regarding nurse-to-patient ratios in each unit and maintain records of actual ratios for each shift in each unit. The bill also requires hospitals to follow certain procedures regarding how ratios are determined, and other staff are prohibited from performing nurse functions unless specifically authorized within a state's scope of practice rules. HHS must adjust Medicare payments to hospitals to cover additional costs attributable to compliance with these ratios. Nurses may object to, or refuse to participate in, an assignment if it would violate minimum ratios or if they are not prepared by education or experience to fulfill the assignment without compromising the safety of a patient or jeopardizing their nurse's license. Hospitals may not (1) take adverse actions against a nurse based on the nurse's reasonable refusal to accept an assignment; or (2) discriminate against individuals for good faith complaints relating to the care, services, or conditions of the hospital or related facilities. HHS may impose civil monetary penalties on hospitals violating the ratio requirements and must publish the names of such hospitals. The bill provides stipends to the nurse workforce loan repayment and scholarship program and expands the nurse retention grant program to include nurse preceptorship and mentorship projects.
Bill· SS. 1114 (118th)open
United States · United States Congress · 30 March 2023
Expanding Access to Low-Cost Generics Act of 2023 This bill modifies provisions related to market exclusivity for a generic drug. Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug. The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) the applicant certifies that there are no conditions that would prevent commercial marketing of the drug within 75 days of approval and that the applicant intends to do so, (3) a first applicant's application has been pending for at least 33 months, (4) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant, and (5) no first applicant's application has been effectively approved on the date that all such conditions are met. If an applicant fails to begin commercially marketing their drug within 75 days of approval via the aforementioned process, the applicant's approval is deemed tentative and the applicant is no longer eligible for subsequent approvals, unless the applicant certifies that the failure was due to unforeseen issues that have since been resolved.
Resolution· SRESS.Res. 149 (118th)passed
United States · United States Congress · 30 March 2023
This resolution designates the first week of April as National Asbestos Awareness Week. It also urges the Surgeon General to warn and educate people about asbestos exposure, which may be hazardous to their health.
Bill· SS. 1120 (118th)referred
United States · United States Congress · 30 March 2023
Improved Access to Affordable Medications Act This bill modifies provisions relating to the ability of generic drug manufacturers to obtain samples of brand-name drugs for purposes of generic drug development. Under current law, brand-name drug manufacturers must provide sufficient quantities of their products on commercially reasonable, market-based terms to generic drug manufacturers upon request for purposes of generic drug development. Brand-name drug manufacturers are subject to civil actions if they fail to do so. The bill modifies provisions relating to this requirement and the criteria needed for related civil actions, such as specifying that generic drug manufacturers may use certain delivery services to make their requests. Additionally, under current law, generic drug manufacturers must obtain authorization from the Food and Drug Administration (FDA) in order to request sufficient quantities of brand-name drugs that are subject to a Risk Evaluation and Mitigation Strategy (REMS) with elements to ensure safe use (ETASU). The bill requires the FDA to approve an authorization request within 60 days (rather than 120 days), if testing and development does not involve human clinical trials. (The FDA sometimes requires a REMS program for certain drugs with safety risks, which may include restrictions on a drug's distribution through ETASU, such as special requirements for pharmacies that dispense the drug.) The bill also requires brand-name drug manufacturers to post their policies on evaluating and responding to requests from generic drug manufacturers for their products, including relevant contact information and procedures.
Bill· SS. 1079 (118th)referred
United States · United States Congress · 30 March 2023
Assistance for Rural Water Systems Act of 2023 This bill allows the Department of Agriculture (USDA) to provide grants, zero-interest loans, low-interest loans, loan forgiveness, and loan refinancing to certain rural water, wastewater, or waste disposal facilities. USDA may provide such assistance for (1) ensuring public health, safety, and order; and (2) addressing financial hardships.
Bill· SS. 1135 (118th)referred
United States · United States Congress · 30 March 2023
Ally's Act This bill requires private health insurance plans to cover certain hearing devices and systems (e.g., bone-anchored auditory implants) and related items and services. The financial requirements and treatment limitations applicable to such coverage may be no more restrictive than the requirements and limitations for other medical and surgical benefits covered under the plan. Further, a plan may not deny or limit coverage based on the plan's review of the medical necessity of such items or services.
Bill· SS. 1102 (118th)referred
United States · United States Congress · 30 March 2023
Dignity for Aborted Children Act This bill sets out requirements for the disposition of human fetal tissue from an abortion. Specifically, it requires abortion providers to obtain a patient's informed consent for one of two specified methods of disposition. First, patients may choose to retain possession of the tissue. A patient may choose to transfer the tissue to an entity that provides interment or cremation services. Second, the patient may elect to release the tissue to the provider. Providers must ensure any tissue released to them is interred or cremated within seven days of the procedure in a manner consistent with state law regarding the disposal of human remains. Abortion providers must report annually about these requirements and other specified information. The bill provides civil or criminal penalties for violations of disposal, informed consent, and reporting requirements.
Bill· SS. 1132 (118th)referred
United States · United States Congress · 30 March 2023
Accelerated Drug Approval for Prescription Therapies 2.0 Act or the ADAPT 2.0 Act This bill allows applicants seeking Food and Drug Administration (FDA) approval to market a new drug to rely on investigations conducted in certain other countries and addresses related issues. If an applicant seeks market approval for a new drug with an application that relies on at least one investigation that the applicant did not conduct and did not obtain approval to use, the applicant may rely on an investigation that was conducted in certain foreign countries if the drug in question has already been approved in that country. The investigation must have been conducted in Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, the United Kingdom, the European Union, a country in the European Economic Area, or another country that the FDA has found to meet certain requirements. The FDA must make a decision on such an application within 90 days of the application's filing. If the FDA does not take certain actions within that period, the application shall be considered approved. The FDA may require the applicant to conduct postapproval studies of the drug and to submit copies of all promotional materials. The bill also establishes an advisory committee to provide the FDA with recommendations as to each application that relies on a foreign investigation. The FDA must make available on its public website each decision on such an application, including the rationale for the decision and the advisory committee's recommendations.
Resolution· SRESS.Res. 144 (118th)referred
United States · United States Congress · 30 March 2023
This resolution expresses support for implementing a Transgender Bill of Rights that guarantees certain rights for transgender and nonbinary people with respect to public services and accommodations, employment, housing, health care, and other specified areas.
Bill· HRH.R. 12 (118th)referred
United States · United States Congress · 30 March 2023
Women's Health Protection Act of 2023 This bill prohibits governmental restrictions on the provision of, and access to, abortion services. Before fetal viability, governments may not restrict providers from using particular abortion procedures or drugs, offering abortion services via telemedicine, or immediately providing abortion services if delaying risks the patient's health. Furthermore, governments may not require providers to perform unnecessary medical procedures, provide medically inaccurate information, or comply with credentialing or other conditions that do not apply to providers who offer medically comparable services to abortions. Additionally, governments may not require patients to make medically unnecessary in-person visits before receiving abortion services or disclose their reasons for obtaining services. After fetal viability, governments may not restrict providers from performing abortions when necessary to protect a patient's life and health. The same provisions that apply to abortions before viability also apply to necessary abortions after viability. Additionally, states may authorize post-viability abortions in circumstances beyond those that the bill considers necessary. Further, the bill recognizes an individual's right to interstate travel, including for abortion services. The bill also prohibits governments from implementing measures that are similar to those restricted by the bill or that otherwise single out and impede access to abortion services, unless the measure significantly advances the safety of abortion services or health of patients and cannot be achieved through less restrictive means. The Department of Justice, individuals, or providers may sue states or government officials to enforce this bill, regardless of certain immunity that would otherwise apply.
Bill· HRH.R. 1955 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Health Resources and Services Administration for maternal and child health.
Bill· HRH.R. 1954 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Health Resources and Services Administration's Health Workforce, Construction and Capital Improvement Costs account.
Bill· HRH.R. 1953 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Health Resources and Services Administration for primary health care.
Bill· HRH.R. 1966 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for public health scientific studies.
Bill· HRH.R. 1973 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for its Buildings and Facilities account.
Bill· HRH.R. 1965 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for the Birth Defects, Developmental Disabilities, Disabilities and Health account.
Bill· HRH.R. 1972 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for public health preparedness and response.
Bill· HRH.R. 1964 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for chronic disease prevention and health promotion.
Bill· HRH.R. 1971 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for global health.
Bill· HRH.R. 1963 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for emerging and zoonotic infectious diseases.
Bill· HRH.R. 1962 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for HIV/AIDS, viral hepatitis, sexually transmitted diseases, and tuberculosis prevention.
Bill· HRH.R. 1961 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for immunization and respiratory diseases.
Bill· HRH.R. 1960 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Health Resources and Services Administration's Program Management account.
Bill· HRH.R. 1959 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Health Resources and Services Administration for family planning.
Bill· HRH.R. 1958 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Health Resources and Services Administration for rural health.
Bill· HRH.R. 1957 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Health Resources and Services Administration for health care systems.
Bill· HRH.R. 1956 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Health Resources and Services Administration for the Ryan White HIV/AIDS Program. (This program provides federal funds to eligible metropolitan areas, states, and local community-based organizations to assist with health care costs and support services for individuals and families affected by HIV/AIDS.)
Bill· HRH.R. 1999 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Office of the Director of the National Institutes of Health.
Bill· HRH.R. 1988 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the National Institute of Nursing Research.
Bill· HRH.R. 1998 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the National Center for Advancing Translational Sciences. (The center works with patient organizations, researchers, and clinicians to develop tools, technologies, and approaches to advance biomedical research and treatments.)
Bill· HRH.R. 1997 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the National Library of Medicine.
Bill· HRH.R. 1987 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the National Institute on Deafness and Other Communication Disorders.
Bill· HRH.R. 1996 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the John E. Fogarty International Center. (The center advances the mission of the National Institutes of Health by supporting global health research conducted by U.S. and international investigators, building partnerships between health research institutions in the U.S. and abroad, and training scientists to address global health needs.)
Bill· HRH.R. 1976 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the National Heart, Lung, and Blood Institute.
Bill· HRH.R. 1995 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the National Institute on Minority Health and Health Disparities.
Bill· HRH.R. 1994 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the National Center for Complementary and Integrative Health.
Bill· HRH.R. 1975 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the National Cancer Institute.
Bill· HRH.R. 1968 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for injury prevention and control.
Bill· HRH.R. 1967 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention for environmental health.
Bill· HRH.R. 1974 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Centers for Disease Control and Prevention (CDC) for CDC-wide activities and program support.
Bill· HRH.R. 2004 (118th)referred
United States · United States Congress · 29 March 2023
This bill limits FY2024 funding for the Substance Abuse and Mental Health Services Administration for substance abuse prevention.
PreviousPage 26 of 27Next